000110876 001__ 110876
000110876 005__ 20230519145618.0
000110876 0247_ $$2doi$$a10.1093/rheumatology/keab401
000110876 0248_ $$2sideral$$a127539
000110876 037__ $$aART-2021-127539
000110876 041__ $$aeng
000110876 100__ $$aTejera Segura, Beatriz
000110876 245__ $$aRelevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
000110876 260__ $$c2021
000110876 5060_ $$aAccess copy available to the general public$$fUnrestricted
000110876 5203_ $$aSLE can affect any part of the gastrointestinal (GI) tract. GI symptoms are reported to occur in >50% of SLE patients. To describe the GI manifestations of SLE in the RELESSER (Registry of SLE Patients of the Spanish Society of Rheumatology) cohort and to determine whether these are associated with a more severe disease, damage accrual and a worse prognosis. METHODS: We conducted a nationwide, retrospective, multicentre, cross-sectional cohort study of 3658 SLE patients who fulfil =4 ACR-97 criteria. Data on demographics, disease characteristics, activity (SLEDAI-2K or BILAG), damage (SLICC/ACR/DI) and therapies were collected. Demographic and clinical characteristics were compared between lupus patients with and without GI damage to establish whether GI damage is associated with a more severe disease. RESULTS: From 3654 lupus patients, 3.7% developed GI damage. Patients in this group (group 1) were older, they had longer disease duration, and were more likely to have vasculitis, renal disease and serositis than patients without GI damage (group 2). Hospitalizations and mortality were significantly higher in group 1. Patients in group 1 had higher modified SDI (SLICC Damage Index). The presence of oral ulcers reduced the risk of developing damage in 33% of patients. CONCLUSION: Having GI damage is associated with a worse prognosis. Patients on a high dose of glucocorticoids are at higher risk of developing GI damage which reinforces the strategy of minimizing glucocorticoids. Oral ulcers appear to decrease the risk of GI damage. © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.
000110876 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000110876 590__ $$a7.046$$b2021
000110876 592__ $$a1.563$$b2021
000110876 594__ $$a8.5$$b2021
000110876 591__ $$aRHEUMATOLOGY$$b6 / 34 = 0.176$$c2021$$dQ1$$eT1
000110876 593__ $$aRheumatology$$c2021$$dQ1
000110876 593__ $$aPharmacology (medical)$$c2021$$dQ1
000110876 655_4 $$ainfo:eu-repo/semantics/article
000110876 700__ $$aAltabás González, Irene
000110876 700__ $$aRúa-Figueroa, Iñigo
000110876 700__ $$aPérez Veiga, Natalia
000110876 700__ $$aDel Campo Pérez, Victor
000110876 700__ $$aOlivé-Marqués, Alejandro
000110876 700__ $$aGalindo, María
000110876 700__ $$aCalvo, Jaime
000110876 700__ $$aOvalles-Bonilla, Juan Gabriel
000110876 700__ $$aFernández-Nebro, Antonio
000110876 700__ $$aMenor-Almagro, Raúl
000110876 700__ $$aTomero, Eva
000110876 700__ $$aDel Val Del Amo, Natividad
000110876 700__ $$aUriarte Isacelaya, Esther
000110876 700__ $$aMartínez-Taboada, Víctor Manuel
000110876 700__ $$aAndreu, Jose L
000110876 700__ $$aBoteanu, Alina
000110876 700__ $$aNarváez, Javier
000110876 700__ $$aMovasat, Atusa
000110876 700__ $$aMontilla, Carlos
000110876 700__ $$aSenabre Gallego, Jose Miguel
000110876 700__ $$aHernández-Cruz, Blanca
000110876 700__ $$aAndrés, Mariano
000110876 700__ $$aSalgado, Eva
000110876 700__ $$aFreire, Mercedes
000110876 700__ $$aMachín García, Sergio
000110876 700__ $$aMoriano, Clara
000110876 700__ $$aExpósito, Lorena
000110876 700__ $$aPérez Velásquez, Clara
000110876 700__ $$aVelloso-Feijoo, M L
000110876 700__ $$aCacheda, Ana Paula
000110876 700__ $$aLozano-Rivas, Nuria
000110876 700__ $$aBonilla, Gema
000110876 700__ $$aArévalo, Marta
000110876 700__ $$aJiménez, Inmaculada
000110876 700__ $$aQuevedo-Vila, Víctor
000110876 700__ $$aManero-Ruiz, Francisco J$$uUniversidad de Zaragoza
000110876 700__ $$aGarcía de la Peña Lefebvre, Paloma
000110876 700__ $$aVázquez-Rodríguez, Tomás Ramón
000110876 700__ $$aIbañez-Rua, Jesús
000110876 700__ $$aCobo-Ibañez, Tatiana
000110876 700__ $$aPego-Reigosa, Jose María
000110876 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000110876 773__ $$g60, 11 (2021), 5329-5336$$pRheumatology (Oxford)$$tRheumatology (Oxford)$$x1462-0324
000110876 8564_ $$s249409$$uhttps://zaguan.unizar.es/record/110876/files/texto_completo.pdf
000110876 8564_ $$s2878199$$uhttps://zaguan.unizar.es/record/110876/files/texto_completo.jpg?subformat=icon$$xicon
000110876 909CO $$ooai:zaguan.unizar.es:110876$$particulos$$pdriver
000110876 951__ $$a2023-05-18-16:12:22
000110876 980__ $$aARTICLE